PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
61.53%
Cash & equivalents growing 61.53% while AGEN's declined -7.80%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
61.53%
Below half of AGEN's -9.27%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.75%
Below half of AGEN's -0.53%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
529.47%
≥ 1.5x AGEN's 20.05%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
588.21%
≥ 1.5x AGEN's 10.89%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
63.35%
≥ 1.5x AGEN's 3.37%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
9.62%
50-75% of AGEN's 18.69%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
59.49%
Less than half of AGEN's -3.40%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
103.88%
≥ 1.5x AGEN's 4.94%. David Dodd sees stronger subscription/prepayment demand.
-531.94%
Exceeding 1.5x AGEN's -9.07%. Michael Burry suspects ballooning short-term obligations vs. competitor.
9.77%
Less than half of AGEN's -2.05%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1866750.00%
Above 1.5x AGEN's 12.86%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
661.90%
Above 1.5x AGEN's 6.98%. Michael Burry sees a potential leverage warning sign.
13.64%
Above 1.5x AGEN's 6.07%. Michael Burry suspects heavy new equity expansion or dilution.
-2.98%
Similar yoy to AGEN's -3.02%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.57%
Below half AGEN's -78.27%. Michael Burry sees potential underperformance in building shareholder capital.
63.35%
≥ 1.5x AGEN's 3.37%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
1244.16%
Above 1.5x AGEN's 24.68%. Michael Burry sees a major jump. Investigate leverage rationale.
-58.28%
Less than half of AGEN's 19.19%. David Dodd sees better deleveraging or stronger cash buildup than competitor.